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Abstract
Background: Body temperature is a strong predictor of outcome in acute stroke. In a previous
randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to
a reduction of body temperature in patients with acute ischemic stroke, even when they had no
fever. The purpose of the present trial was to study whether this effect of acetaminophen could be
reproduced, and whether ibuprofen would have a similar, or even stronger effect.
Methods: Seventy-five patients with acute ischemic stroke confined to the anterior circulation
were randomized to treatment with either 1000 mg acetaminophen, 400 mg ibuprofen, or placebo,
given 6 times daily during 5 days. Treatment was started within 24 hours from the onset of
symptoms. Body temperatures were measured at 2-hour intervals during the first 24 hours, and at
6-hour intervals thereafter.
Results:  No difference in body temperature at 24 hours was observed between the three
treatment groups. However, treatment with high-dose acetaminophen resulted in a 0.3°C larger
reduction in body temperature from baseline than placebo treatment (95% CI: 0.0 to 0.6 °C).
Acetaminophen had no significant effect on body temperature during the subsequent four days
compared to placebo, and ibuprofen had no statistically significant effect on body temperature
during the entire study period.
Conclusions: Treatment with a daily dose of 6000 mg acetaminophen results in a small, but
potentially worthwhile decrease in body temperature after acute ischemic stroke, even in
normothermic and subfebrile patients. Further large randomized clinical trials are needed to study
whether early reduction of body temperature leads to improved outcome.
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Background
During the first days after stroke, between one and two
fifths of the patients develop fever or subfebrile tempera-
tures. [1–4] Increased temperatures have been associated
with relatively large infarct volumes, high case fatality,
and poor functional outcome, even after adjustment for
initial stroke severity [2–6]. The period in which hyper-
thermia is associated with poor outcome is probably lim-
ited to the first 12 or 24 hours from stroke onset.[6,7]
The harmful effects of an early rise in body temperature
have been attributed to increased cerebral metabolic de-
mands,[8] changes in the blood-brain barrier permeabili-
ty, acidosis, and an increased release of excitatory amino
acids.[9] In animal models of temporary focal cerebral
ischemia, mild intra-ischemic hyperthermia increased in-
farct volume [10], whereas mild hypothermia reduced in-
farct size.[11]
The above suggests that pharmacological reduction of
temperature in patients with acute ischemic stroke may
improve their functional outcome. In a previous rand-
omized trial, we observed that treatment with acetami-
nophen in a daily dose of 6000 mg after ischemic stroke
led to a 0.4°C (95% CI: 0 to 0.8°) lower body tempera-
ture at 12 and 24 hours than treatment with placebo; a
daily dose of 3000 mg did not result in a significant reduc-
tion of body temperature.[12] Other studies in which low-
er dosages were used yielded promising, but inconclusive
results[13,14]. Several studies in adults and children with
fever suggest a larger antipyretic effect from ibuprofen
than from acetaminophen. [15–17] The effect of ibupro-
fen on body-core temperature in normothermic and sub-
febrile patients with stroke, who may have a disturbance
of thermoregulation [18], has not been studied.
The aim of our study was to test the effect of high-dose
ibuprofen and to confirm the previously observed reduc-
ing effect of high-dose acetaminophen on body tempera-
ture. After 1 positive and 2 negative trials [12–14], a
confirmation of the effect of high dose acetaminophen on
body temperature in acute stroke seemed necessary, be-
fore we could decide to embark on a larger phase III trial
of antipyretic treatment in acute stroke.
Methods
Design
Our study was a three-arm, randomized, double blind,
placebo-controlled clinical trial, performed in two univer-
sity hospitals and in one regional hospital. The protocol
for this study has been published.[19]
Patients could be included if they had acute ischemic
stroke in the anterior circulation, a body temperature be-
tween 36.0°C and 39.0°C, a computed tomography (CT)
scan that was compatible with acute ischemic stroke, a fo-
cal deficit without rapid improvement, and a possibility
to start treatment within 24 h after stroke onset. Patients
with a posterior circulation stroke were not included be-
cause occasional patients could have severe disturbances
of temperature regulation through involvement of the hy-
pothalamus. Patients were excluded if they had severe
aphasia, defined as a score of 2 or 3 on question no. 9 of
the NIH Stroke Scale (NIHSS) [20] because they could not
be expected to understand the information about the
study. Other exclusion criteria were: treatment with an
NSAID that could not be stopped (low dose aspirin was
not an exclusion criterion), hypersensitivity to ibuprofen
or acetaminophen, (chronic) liver failure or cirrhosis,
(chronic) renal failure, a history of alcohol abuse, active
ulcer disease or a history of peptic ulceration or gastro-in-
testinal hemorrhage in the preceding year, colitis ulcerosa,
pregnancy, use of corticosteroids, a severe concomitant
medical condition that could affect the assessment of the
effect of the study medication on temperature, residual
neurological impairment resulting from a previous stroke
that might hamper the assessment of functional outcome,
and death appearing imminent.
All patients were given verbal and written information
about the potential risks and benefits of participation in
the study. They gave consent in writing prior to randomi-
zation. We obtained the approval of the medical ethics
committees of each participating center for the conduct of
this study, and we complied with the Helsinki
declaration.[21]
The NIH Stroke Scale was used to assess stroke severity at
onset, and the modified Rankin scale to determine the pa-
tients' pre-stroke functional status. Laboratory investiga-
tions included a full blood count, glucose, electrolytes,
creatinine, liver functions, and C-reactive protein (CRP).
Body-temperature was measured with a tympanic ther-
mometer at 2-hourly intervals during the first 24 hrs after
start of treatment, and thereafter every 12 hours until day
7. Temperatures were taken from the left and the right ear,
and averaged. The baseline temperature (at the start of
treatment) and temperature at 24 hours after start of treat-
ment were determined both by rectal and tympanic ther-
mometry. Rectal measurements were considered more
reliable, and were therefore used for assessment of the pri-
mary outcome, body temperature at 24 hours after start of
treatment, and for assessment of body temperature at in-
clusion into the study. Tympanic measurements were
used for the other temperature measurements because
they were considered less invasive and burdensome to the
patients. However, as tympanic measurements are less
precise, we used rectal temperatures in our analyses at 0
and 24 hours. Compliance was measured by countingBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/2
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leftover pills, and by a registry of the medication that was
actually taken. All patients were treated with low dose (30
mg) aspirin, after a loading dose of 300 mg.
Study medication
Patients were treated for 5 days with acetaminophen or
ibuprofen in daily doses of 6 × 1000 mg or 6 × 400 mg,
respectively, or with matched placebo. Study drugs were
administered through identical capsules. The first dose of
medication could be given as an identical suppository.
The study medication was provided in white paper boxes,
numbered consecutively with a study number.
Randomization and blinding
Treatment allocation was random. The randomization
was blocked in lots of six and stratified for the time since
onset of stroke (0 to 12 hours versus 12 to 24 hours). A
computer-generated list, provided by an independent stat-
istician (PM), containing the medication number and in-
formation on the nature of the treatment (placebo,
acetaminophen, or ibuprofen) resided only with the inde-
pendent safety committee and with the study pharmacist.
The treatment allocation of any patient could be disclosed
before termination of the study if the safety committee
deemed this necessary. Local clinical investigators could
apply for disclosure of the treatment allocation of an indi-
vidual patient by the study pharmacist.
Adverse events
Serious adverse events were defined as any potentially life-
threatening deterioration in health status within the
study-monitoring period (day 0 to day 7). These included
any infection, such as pneumonia, sepsis, or urinary tract
infection that needed antibiotic treatment according to
the judgment of the treating physician, any liver function
disturbance (aspartate aminotransferase (ASAT), alanine
aminotransferase (ALAT), alkaline phosphatase (AF), or
total bilirubine levels exceeding twice the local upper lim-
it of normal), gastro-intestinal hemorrhage, and any neu-
rological deterioration (i.e. a decrease in level of
consciousness of more than one point on the Glasgow
coma scale, or an increase of two or more points on the
NIHSS). An independent, unblinded safety and data
monitoring committee reviewed all serious adverse events
on a two-weekly basis.
Outcomes
The primary outcome was body temperature measured
rectally at 24 hours from start of treatment. Secondary
outcomes were change from baseline temperature at 1 and
5 days from start of treatment, and time with elevated
body temperature (> 37.0°C) (area under the curve) dur-
ing the first 24 hours and the first five days. The tertiary
outcome was functional outcome at 1 month, as deter-
mined by the scores on the modified Rankin Scale (mRS)
and Barthel Index (BI). The Barthel index is a reliable and
valid measure of the ability to perform activities of daily
living such as eating, bathing, walking, and using the toi-
let. Patients able to perform all activities with complete in-
dependence are given a score of 20.[22] The modified
Rankin scale is a reliable, simplified overall assessment of
handicap in which a score of 0 indicates the absence of
symptoms and a score of 5, severe disability.[23]
Statistical analysis
The study results were analyzed on an intent-to-treat ba-
sis. An "on-treatment" analysis of primary and secondary
endpoints was planned. There was no formal interim
analysis. The main results of the study are presented as the
mean difference in temperature between each treatment
group and the placebo group. The precision of these esti-
mates was expressed with 95% confidence intervals, based
on the t distribution. No adjustments for multiple com-
parisons were made. We planned to use multiple linear re-
gression to adjust for possible confounding factors, such
as age, stroke type, and stroke severity, but this was not
considered necessary.
In order to detect a difference in core body temperature of
0.5°C, with a significance level of α = 0.05, and power 1-
β = 0.80, at least 23 patients would be needed in each
treatment group; this was rounded to 25. In total, 75 pa-
tients were included in this study.[19]
Results
Baseline characteristics
Seventy-five patients were randomized and included in
the study between October 2000 and October 2001. Al-
most half of the patients started treatment within 12
hours after onset of symptoms. Prognostic factors, and
other factors that could be related to increased body tem-
perature were evenly distributed amongst the three treat-
ment groups (Table 1). However, patients in the
acetaminophen group had a lacunar stroke less often, they
had a higher score on the NIHSS and were drowsy more
often, and the mean body temperature at the start of treat-
ment was higher than in the placebo group (0.3°C).
Patient flow
All but one patient were on treatment after 24 hours.
Twenty-six patients did not complete the full five-day-
treatment schedule (Figure 1). Of the 7 patients in the pla-
cebo group who stopped, 4 were discharged within 5 days,
2 withdrew their consent, and 1 patient forgot to take the
last 3 doses on day 5. In the ibuprofen group, 6 patients
were discharged within 5 days, 2 withdrew consent, and 2
developed a hemorrhagic gastritis. Finally, in the acetami-
nophen group, one patient, a woman with a severe mid-
dle cerebral artery infarction did not complete the first 24
hours of treatment, and died from herniation afterBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/2
Page 4 of 8
(page number not for citation purposes)
hemorrhagic transformation of the infarct. One other pa-
tient on acetaminophen died from progressive stroke
within the first five days. Four patients were discharged
early, one patient had a high serum creatinine, one had
slightly elevated transaminases at baseline, which made
the local investigator decide to stop the study treatment
and finally, one patient withdrew consent. Patients who
died within the study period or who had stopped taking
their medication, could still be considered as having com-
pleted the 28-day outcome assessment.
Outcome
At 24 hours, the mean rectal body temperatures in the
three groups did not differ significantly (Table 2). Howev-
er, compared with placebo, treatment with acetami-
nophen resulted in a 0.3°C (95% CI: 0.0 to 0.6°C) larger
reduction in body temperature in the first 24 hours. This
effect occurred early and was stable (Figure 2). In the first
24 hours, ibuprofen had no significant effect on body
temperature as compared with placebo. The difference in
reduction in body temperature at 24 hours after start of
treatment between ibuprofen and acetaminophen was
0.2°C (95% CI: -.2°C to 0.6°C).
Body temperature measurements at five days from the
start of treatment were available in 52 of the 75 patients.
In the 21 patients who died, withdrew consent, or were
discharged within 5 days from randomization, no further
temperatures could be taken, and in 2 other patients who
had discontinued study treatment, temperature measure-
ments were inadvertently stopped. After the first day,
mean body temperatures tended to be lower in both
groups who were on active treatment (Figure 2). After 5
days, ibuprofen treatment resulted in 0.5°C lower body
temperatures, and acetaminophen treatment led to 0.2°C
lower body temperatures than placebo treatment, but
these differences were not statistically significant (Table
2). In addition, only about half of the patients were still
on treatment on day 5.
The comparison between the areas under the temperature
curve was hampered by differences in temperature at start
of treatment. After adjustment for differences in baseline
temperature, the areas for acetaminophen and ibuprofen
were significantly smaller than for placebo. Finally, no sig-
nificant differences in functional outcome were observed
between the three regimens (Table 2).
Adverse events
During the treatment period, 1 patients died from hernia-
tion and 1 from a a progressive stroke, both were on aceta-
minophen. One patient (on acetaminophen) developed
pneumonia, and two patients (both on ibuprofen) had
gastric retention and signs of hemorrhagic gastritis. Liver
function disturbances occurred in 3 patients who were on
placebo, in 6 patients who used ibuprofen, and in 6
patients who used acetaminophen, resulting in a relative
risk of 1.9 (95% CI: 0.5 to 6.7) of acetaminophen
Table 1: Demographics, stroke risk factors and clinical characteristics of the study population.
Acetaminophen (n = 26) Ibuprofen (n = 24) Placebo (n = 25)
Demographics
Age in years (m, SD) 69 (16) 67 (15) 65 (10)
Male sex 17 (65%) 16 (67%) 16 (64%)
Risk factors for stroke
Hypertension 12 (46%) 7 (29%) 8 (32%)
Atrial fibrillation 6 (24%) 7 (29%) 1 (4%)
Peripheral vascular disease 4 (15%) 1 (4%) 1 (4%)
Diabetes mellitus 1 (4%) 4 (17%) 3 (12%)
Previous TIA 5 (19%) 3 (13%) 3 (12%)
Previous stroke 3 (12%) 8 (33%) 2 (8%)
Cigarette smoking 14 (54%) 13 (54%) 16 (64%)
Stroke characteristics
Lowered consciousness level 5 (19%) 2 (8%) 2 (8%)
Aphasia 7 (27%) 9 (37%) 6 (24%)
NIHSS (m, SD) 18 (14) 12 (10) 14 (11)
Lacunar stroke 8 (31%) 6 (25%) 11 (44%)
Other clinical characteristics
Treatment within 0–12 hours 14 (54%) 14 (58%) 12 (48%)
Temp. at admission (°C) (m, SD) 37.2 (0.6) 37.0 (0.6) 37.0 (0.5)
Temp. at start of treatment (°C) (m, SD) 37.3 (0.5) 37.1 (0.7) 37.0 (0.5)
Acetaminophen is given in a dose of 1000 mgs, 6 times daily, and ibuprofen in a dose of 400 mg 6 times daily. Values are absolute numbers with per-
centages of totals in the treatment arms, unless stated otherwise. 'm' indicates mean, 'SD' standard deviation.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/2
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compared to the placebo group. According to the local in-
vestigators, the liver function disturbances and the gastic
disturbances were possibly related to the study treatment.
Discussion
We studied the effect of two common antipyretic agents
on body temperature after acute ischemic stroke. Patients
on acetaminophen had a more severe stroke at baseline,
and had higher body temperatures at the start of treat-
ment. No differences in mean body temperature after 24
hours of treatment (the primary outcome measure) were
observed between the three study groups, because of dif-
ferences in baseline temperature. However, acetami-
nophen in a daily dose of 6000 mg led to 0.3°C (95% CI:
0.0 to 0.6°C) larger reduction of body temperature than
placebo after 24 hours. This effect was similar to the effect
that was observed in a previous study.[12] The effect of
ibuprofen was smaller and not statistically significant.
Figure 1
Patient flow in the trial.
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There was a trend towards a temperature-reducing effect
of ibuprofen at 5 days, but this was based on observations
in only about two-thirds of the patients. It is doubtful
whether temperature reduction several days after the on-
set of cerebral ischemia will have potential therapeutic
effects.
No statistically significant differences in functional out-
come were observed between the treatment groups. This
was expected, as our study was not powered for that
purpose.
Validity
Although all but one patient completed the first 24 hours
of treatment and underwent the primary outcome assess-
ment, only 50 (67%) of the 75 patients completed the 5-
day treatment period. This was caused by the general pol-
icy to discharge patients as early as possible from the hos-
pital to home.
In this study, we used rectal temperatures as a primary
outcome measure, and not intracranial or intravesical
temperatures as an approximate to brain temperature. In
a study of moderate hypothermia in patients with trau-
matic brain injury, rectal temperatures remained very
close to brain temperatures.[24] In addition, in the Co-
penhagen study, that demonstrated a convincing
relationship between temperature and outcome, only rec-
tal body temperatures were measured.[6]
Our study is not large enough to allow for a direct com-
parison of the effects of acetaminophen and ibuprofen on
body temperature in stroke. Thus, we cannot totally ex-
clude that ibuprofen is more effective than acetami-
nophen. Treatment with 30 mgs of aspirin daily, after a
loading dose of 300 mg could not have confounded our
results, because it was given to all patients, and much
higher dosages are needed to treat fever.
Other studies
In three other studies, acetaminophen has been used in an
attempt to lower body temperature in patients with acute
stroke. Koennecke et al. conducted a comparable study
and showed that treatment with acetaminophen in a daily
dose of 4000 mg resulted in a substantial reduction of the
proportion of patients with body temperatures over
37.5°C: 5% of the patients who were treated with a daily
dose of 4 g acetaminophen developed body temperatures
over 37.5°C, against 36% in the placebo-group.[13] The
authors did not report the size of the temperature reduc-
tion. Kasner et al. conducted a partly blinded trial of
acetaminophen against placebo in 39 patients with hem-
orrhagic or ischemic stroke, and observed a difference of
0.2 °C in body temperature in favor of active treatment.
The patients who received acetaminophen tended to be
more often hypothermic (<36.5°C) and less often hyper-
thermic (>37.5°C), but these results were not statistically
significant.[14] In this study, a lower daily dose of aceta-
minophen (3.9 g) was used than in our study (6 g). In our
previous study, we observed that treatment with high-
dose, but not low-dose acetaminophen led to a 0.4°C
(95% CI: 0 – 0.8°) lower body temperature at and 24
hours than treatment with placebo.[12] The present study
confirms this effect.
In a recent study it was shown that the concomitant ad-
ministration of ibuprofen but not acetaminophen antag-
onizes the irreversible platelet-inhibiting effect of
aspirin.[25] Ibuprofen may therefore limit the already
small beneficial effect of aspirin to improve outcome after
ischemic stroke.[26] This is an additional reason why
acetaminophen may be preferable to ibuprofen for reduc-
tion of temperature in patients with acute stroke.
Ethical considerations
Because of the consistently observed relation between
hyperthermia and poor outcome after stroke, many physi-
cians want to treat their stroke patients who have a raised
temperature with antipyretic drugs.[27,28] However, a
causal relationship between hyperthermia and poor out-
come has never been demonstrated, and subfebrile tem-
peratures and fever may just be epiphenomena of severe
brain damage. In addition, there is no evidence that a
pharmacological reduction of increased temperatures will
lead to an improved outcome. Preventive administration
Figure 2
Time course of change in tympanic body temperature com-
pared to start of treatment during the first 24 hours of treat-
ment, in the three treatment groups. Discrepancies with 
Table 2 are caused by rounding and by the use of tympanic 
measurements.
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of antipyretics may even mask infections and lead to de-
layed treatment with antibiotics. For these reasons, we
think that the efficacy of antipyretic drugs to improve out-
come after stroke has to be proven in a randomized
controlled trial before treatment with these agents is ac-
cepted as a standard procedure. For the same reasons, we
do not consider it unethical to withhold antipyretics from
stroke patients with (sub-)febrile temperatures in the pla-
cebo arm of such a trial.
Conclusions
Treatment with a daily dose of 6000 mg acetaminophen
results in a small, but potentially worthwhile decrease in
body temperature after acute ischemic stroke, even in nor-
mothermic and subfebrile patients. Further large rand-
omized clinical trials are needed to study whether this
early reduction of body temperature leads to improved
outcome. A large, pragmatic multicenter trial of high dose
acetaminophen in acute stroke will be launched in 2003.
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